

Examination of Blood Clotting

Pathophysiological Aspects

Jan Živný

Department of Pathophysiology

jzivny@LF1.cuni.cz

Outline

- **Hemostatic And Coagulation Abnormalities**
- **Thrombosis**
 - Basic mechanisms
 - DVT/PE
 - Laboratory approach to hypercoagulation
- **Hemorrhage**
 - Primary hemostasis (platelets and vessel wall defects)
 - Secondary hemostasis (Plasma coagulation factors)
 - Case Report


Hemostatic And Coagulation Abnormalities



Hemostatic abnormalities can result in procoagulation or/and anti-coagulation conditions

- **Thrombophilia - Thrombosis / embolia**
- **Hemorrhage**

Hemostasis is a integral part of inflammatory response


HEMOSTASIS = the arrest of bleeding
from an injured vessel





Thrombosis and Embolia

Thrombophilia (hypercoagulability) is the predisposition to develop thrombosis due to an abnormality in the system of hemostasis




Pathogenesis of Thrombosis

Virchow's triad


Thrombi are formed as a result of the one or more abnormalities in:

- blood vessels
- blood flow
- blood coagulability




Rudolf Virchow (1821-1902)

Thrombosis And Embolia




VENOUS THROMBOSIS



Deep Venous Thrombosis (DVT)

CLINICAL MANIFESTATION OF DVT

- Asymptomatic:
 - cause of > 50% of PE
- Symptomatic:
 - swelling
 - pain or palpation pain
 - changes in color and temperature of skin
 - Homan's sign
 - Increased resistance or calf pain during dorsiflexion of foot



Postthrombotic syndrome

(CLINICAL MANIFESTATION OF DVT)

- sign of chronic DVT
- Usually develops 2-15 years after the episode DVT
 - varicose surface veins
 - erythema, dermatitis
 - skin ulcerations (lower extremities)

The incidence of PTS after symptomatic iliofemoral DVT

- 25-50% at 2 years
- 70-90% after 7-10 years

Laboratory markers of thrombosis

Fibrin(ogen) degradation products concentration


(FDP) <1000 $\mu\text{g/L}$

- haemocoagulation failure
- ELISA or semi quantitative agglutination methods


D-dimer: < 500 $\mu\text{g/L}$

- cross-linked FDPs specific for stable fibrin
- high sensitivity but low specificity for DVT/PE

Fibrinogen Degradation



Plasmin degrades fibrin into fragments of many sizes, most of which are detected by the D-Dimer assay



Imaging Methods to Confirm DVT

- Real time ultrasound with Doppler
 - 24-66% sensitivity
- Magnetic resonance imaging (MRI)
- Contrast venography
 - 5-10% complication (phlebitis)
- Impedance pletysmography
- Accumulation of 125I-Fibrinogen ???
 - low specificity (false positive)

Pulmonary embolism (PE)

CLINICAL MANIFESTATION OF DVT / PE

- complication of DVT
- Symptoms and signs depend on the extend of embolism:
 - dyspnea, tachypnea, tachycardia
 - pleuritic chest pain
 - increased jugular vein filling
 - hemoptysis (expectoration of blood)
 - cardiovascular failure and sudden death

Diagnosis Of PE

- Ventilation / Perfusion lung scan
 - recommended in all clinically stabilized pts with suspicion
- CT pulmonary angiography (CTPA)
 - referred also as CAT scan

???

- Right ventricular heart catetrization
- Echocardiography
- Blood gas analysis (ABG) ?
- ECG ?
- Chest X-ray ?

Abnormal ventilation-perfusion (LR lobe)

1 anterior perfusion




Rt
400K
Lt
66s

1 posterior perfusion



Lt
400K
Rt
63s

1 lpo perfusion



Lt
400K
Rt
86s

1 rpo perfusion



Lt
400K
Rt
85s

1 anterior ventilation




Rt
300K
Lt
84s

1 posterior ventilation




Lt
300K
Rt
65s

1 lpo ventilation



Lt
300K
Rt
107s

1 rpo ventilation



Lt
300K
Rt
87s

Laboratory Approach to Hypercoagulation states

- **Antithrombin activity (AT):**
 - normal 100-80 % of control plasma activity
 - deficiency of AT increase the risk of thrombophilia and DIC
- **APCR (Activated Protein C Resistance)**
 - Factor V Leiden
 - Polymerase Chain Reaction (PCR) and Restriction fragment length polymorphism (RFLP)
- Assays of specific anticoagulant proteins

Hemorrhage


Primary hemostasis

Platelets and vessel wall defects

Secondary hemostasis

Plasma coagulation factors



Hemorrhage



PRIMARY HEMOSTASIS

complex defense reaction which
involve platelets and vessel wall

VASOCONSTRICTION AND
AGGREGATION



Platelets and von Willebrand factor

Platelet count (PLT) - 150k - 400k / μ L

- for surgery optimal $> 100k / \mu L$
- severe thrombocytopenia $PLT < 20k / \mu L$

Mean platelet volume (MPV) - 6 - 8 fL

- some hereditary thrombocytopathies have large PLT

Aggregometry


- used for classification of congenital platelet disorders
- Aggregation is induced in PLT rich plasma or in WB collected to sodium citrate by the addition of activator (ADP, thrombin, collagen)

Bleeding Time (Duke 1910, Ivy 1941)

- Functional test of primary hemostasis (platelets)
- Time required for spontaneous hemostasis after the standard injury

- Duke: Standard incision of ear auricle 2-5 min.
- Ivy: Standard incision (6x1 mm) on the volar aspect of the forearm, with the BP cuff inflated to 40 mm Hg (Ivy) 4-8 min

Bleeding Time - Ivy



Prolonged:


- thrombocytopenia (< 100k/mL)
- Disorders of platelet function
- von Willebrand disease
- aspirin (>5 days)

- Standard incision 6x1 mm
- BP cuff inflated to 40 mm Hg
- Normal value: 4-8 min

Idiopathic Thrombocytopenic Purpura



Large ecchymotic area over the thigh following minor trauma. The platelet count at the time was 7000/uL



Bone marrow biopsy showing both megakaryocytic and erythroid hyperplasia


Capillary resistance test (Rumpel-Leede)

- Test of capillary vessel wall integrity
 - diagnosis of hereditary purpuras (e.g. Weber-Rendu-Osler pupura)
- Number of petechiae on the forearm area (4x4 cm) after the application of standard pressure of 10,5 kPa for 10 min using a BP cuff
- > 5 petechiae indicates increased fragility of capillaries -

SECONDARY HEMOSTASIS

- Proteolytic cleavage of plasma coagulation factors

Plasma Coagulation Factors



Venepuncture

Tourniquet is applied
and area is disinfected



Needle is introduced
into vein, blood is drawn
into vial and analyzed




ADAM.

Blood is collected into tubes with acid citrate dextrose (ACD) and centrifuged to obtain platelet poor plasma (PPP)

Prothrombin Time = PT (Quick's test)

- Fibrin fibers appearance (i.e. Clotting time) is measured after the addition of thromboplastin (TF and phospholipids) to recalcified (CaCl_2) plasma
- Use:
 - monitor therapy with coumarin (max. **INR = 4.5**)
 - test of the liver biosynthesis
 - screening for disordered coagulation



Prothrombin Time

(PT)

Citrated Plasma $\xrightarrow[\text{(Brain)}]{\text{Tissue Factor}}$ $\xrightarrow{\text{Calcium}}$ Thrombin
(Placenta)
(Lung)

Fibrinogen $\xrightarrow{\text{Thrombin}}$ Fibrin

Factors: VII, X, V, II, Fibrinogen

International Normalized Ratio

$$\text{INR} = \left(\frac{\text{Patient Pro Time}}{\text{Mean Normal Pro Time}} \right)^{\text{ISI}}$$

ISI = A function of the relationship between working and WHO thromboplastins

Ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the ISI value for the analytical system used.

ISI usually between 1.0 and 1.4

Prothrombin Time = PT (Quick's test):

Longer PT:

- deficiency of FV or vit. K dependent FII, VII, IX, X
- severe FBG deficiency
- hi FDP
- In some settings is not influenced by heparin (to 1 U/mL)
- Normal values: 11-14 s (INR 0.9-1.1)

Activated partial thromboplastin time = aPTT


-The clotting time is measured after the addition of phospholipids into the recalcified plasma that has been preincubated with particulate material (e.g. micronized silica or kaolin) to initiate activation of contact system

-Use:

-monitoring of heparin therapy (1.5 - 2.5 fold prolongation)

-contact (intrinsic) factor deficiency XII, PK, HMWK, FXI (hemofilia C), FIX (B) , FVIII (A)

-Lupus anticoagulants



Activated Partial Thromboplastin Time (aPTT)

Citrated PPP $\xrightarrow[\text{(Cephalin)
(Inosithin)}]{\text{Phospholipid}}$ $\xrightarrow[\text{(Silica)
(Celite)
(Kaolin)
(Elagic Acid)}]{\text{Contact Activator}}$ Act. Citrated PPP

Act. Citrated PPP $\xrightarrow{\text{Calcium}}$ Thrombin

Fibrinogen $\xrightarrow{\text{Thrombin}}$ Fibrin

Factors: HMWK, PreKal. XII, XI, IX, VIII, X, V, II, Fibrinogen

Activated partial thromboplastin time = aPTT

Typically 28-36 s

Results are presented as a patients aPTT vs. normal aPTT

-Prolonged test time:

- Deficiency of FII, V, X;
 - Deficiency of contact system (FXII, PK, HMWK); FXI, FIX, FVIII (hemophilia C, B, A)
 - lupus anticoagulants
 - severe deficiency of FBG; high levels of FDP
 - disordered conversion of FBG
- Shorter test time:** Prothrombotic situations

Evaluation of PCS function in acute medicine

Bedside examination

Lee-White test

- coagulation time of whole blood w/o anticoagulant
- - polystyrene or glass tube at 37°C.
- - Normal time 4-10 min. (depends on setting)
- - Function of PCS - fast orientation

Thrombin time of whole blood

- - coagulation time of whole blood collected to the tube with standard amount of thrombin
- - Presence of fibrinogen YES / NO
- - DIC decompensation- fast screening method

Activated coagulation time (ACT)

- blood drawn w/o anticoagulant is transferred to the tube with contact activator (silica or kaolin) and mixed at 37°C until coagulum is present (normal about 150 s).
- Routine use for
 - the heparinization control of extracorporeal circulation or hemodialysis (required 180-300 s)
 - the heparinization control of extracorporeal circulation during heart surgery > 600 s

CASE REPORT: KOA 1

F, 55 years

At 26

- 10 days after 3rd delivery - DVT of lower right extremity and SVT of lower left extremity
- Therapy with heparin then OA with warfarin 6 month

At 41, 43

- 2 uncomplicated gyn. surgeries (ovarial cyst)

At 45

- Episodes of tachycardia: ECHO showed mitral stenosis

At 46, 53, 54: SVT of lower extremities

Clinical diagnosis

Thrombophilia

What is the cause of thrombophilia?

Inherited causes

Acquired causes

Acquired thrombophilia

- Increased viscosity of the blood (dehydration, polycythemia)
- Increased central venous pressure and reduced leg veins flow – e.g. neoplasm, **pregnancy**, stenosis
- Oral contraceptive use
- Vitamin K deficiency
- Cancer
- Anti-phospholipid antibodies
- DIC (acute, chronic)
- Liver failure
- Massive injury
- Acute infectious disease
- Immobilization longer than 3 days
- etc

Inherited thrombophilia

Factor	General Population	People With Thrombosis
APCR: factor V Leiden mutation	3-8% of Caucasians	20-25%
Prothrombin G20210A	2-3% of Caucasians	4-8%
Antithrombin deficiency	1 in 2-5000	1-1.8%
Protein C deficiency	1 in 300	2.5-5.0%
Protein S deficiency	Unknown	2.8-5.0%
Hyperhomocysteinemia	11%	13.1-26.7%

Inherited anatomical vein variations

KOA 1/II

Test for APC resistance: APC ratio


- aPTT test with and w/o addition of APC

$$\text{APC ratio} = (\text{aPTT w APC} / \text{aPTT w/o APC})$$

Normal APC ratio: 2 - 5


APC resistance < 2

Patient APC ratio = 1.15



APC resistance

- **Factor V (Leiden) mutation**
- Oral contraceptive use
- Pregnancy
- Elevated prothrombin levels due to the G20210A mutation
- Cancer




KOA 1/II

Mutation analysis of FV:

- RFLP PCR (Restriction fragment length polymorphism)
 - PCR amplification of FV DNA fragment (which include 1691) (1691G→A substitution) and subsequent cleavage of PCR product by restriction enzyme MnlI
 - MUTATION CHANGES THE CLEAVAGE SITE = ENZYME DOES NOT CUT THE FRAGMENT

Inheritance of RFLP markers



KOA 1/II


Mutation analysis of FV:

- **ARMS PCR** (amplification refractory mutation system)
 - PCR using mutation specific primers



LAB RESULT homozygose mutation of FV (Leiden mutation) (Arg506Gln)

What is the role of (APC) v PS?

Extrinsic Xase




Intrinsic Xase



Prothrombinase

KOA 1


KOA 1/III Regulation of Thrombin Activity



KOA 1/IV

During hospitalization acute episodes of atrial fibrillation: ECHO revealed thrombus in the LA plus mitral stenosis

Cardiosurgery: Thrombectomy and mitral valve replacement



How it may look like

Wright-Smith G R et al. *Circulation* 1998;98:931-932

Transthoracic echocardiogram showing a large, ball-shaped mass, with an echolucent center, that was freely mobile within the left atrial cavity.

How it may look like



At surgery, the mass was not adherent to the atrial wall and was easily removed from the left atrium.



Cut section of the mass revealed laminated thrombus, giving an onionskin appearance with central cavitation.

Subsequent therapy

Long term therapy with anticoagulants with INR = 3.5 – 4.5

Vit.Kdef./OA

PLT	BT	aPTT	PT	TT	FBG
------------	-----------	-------------	-----------	-----------	------------

N **N** **P** **P** **N** **N**

Factor V^{LEIDEN}

- Risk of thrombosis
 - heterozygous mutation (Factoru V^{LEIDEN}) 7-fold increased risk compared to wt
 - homozygous mutation (Factoru V^{LEIDEN}) 80-fold increased risk compared to wt

Approximately 1 person in 20 develops a DVT in the course of his or her lifetime (~20-25% of them would have Leiden mutation)

To Remember

- Hemostasis is part of inflammatory response
- Bleeding time
- aPTT
- PT (Quick)
 - INR
- Thrombin time (DIC fast screen)
- D-dimer
- APC resistance

Thank you

Principle of the Mixing Study

